SEC Comment Letter 0000000000-24-007255 to Q/C TECHNOLOGIES, INC. (QCLS)
Q/C TECHNOLOGIES, INC.
Date: June 27, 2024 · CIK: 0001321834 · Accession: 0000000000-24-007255
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280415
Letter
United States securities and exchange commission logo June 27, 2024 Joshua Silverman Chairman of the Board MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 623 Baltimore, MD 21205 Re:MyMD Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 21, 2024 File No. 333-280415 Dear Joshua Silverman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alla Digilova
Show Raw Text
United States securities and exchange commission logo
June 27, 2024
Joshua Silverman
Chairman of the Board
MyMD Pharmaceuticals, Inc.
855 N. Wolfe Street, Suite 623
Baltimore, MD 21205
Re:MyMD Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 21, 2024
File No. 333-280415
Dear Joshua Silverman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alla Digilova